Onderzoeker
Anke Maes
- Trefwoorden:Geneeskunde
Affiliaties
- Klinische Biologie (Departement)
Lid
Vanaf17 apr 2023 → Heden - Hematologie (Onderzoeksgroep)
Lid
Vanaf1 sep 2014 → Heden - Basis (bio)-medische wetenschappen (Departement)
Lid
Vanaf1 jan 2020 → 30 sep 2022 - Basis (bio)-medische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 31 dec 2019 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 31 dec 2019 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2019 → 31 dec 2019 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf7 aug 2015 → 18 nov 2019 - Basis (bio)-medische wetenschappen (Departement)
Lid
Vanaf1 sep 2014 → 30 sep 2022 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf14 aug 2012 → 26 jun 2014
Publicaties
1 - 10 van 11
- Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis(2023)
Auteurs: Arne Van der Vreken, Inge Oudaert, Gamze Ates, Sylvia Faict, Philip Vlummens, Hatice Satilmis, Rong Fan, Anke Maes, Ann Massie, Kim De Veirman, et al.
Pagina's: 112-123 - Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma(2023)
Auteurs: Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, et al.
- Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism(2023)
Auteurs: Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M Knight, Nathan De Beule, Gamze Ates, Ann Massie, et al.
Pagina's: 69–80 - The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers(2022)
Auteurs: Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
- Aberrant DNA methylation in multiple myeloma(2022)
Auteurs: Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne
- System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance(2022)
Auteurs: Fang Wang, Inge Oudaert, Chenggong Tu, Anke Maes, Arne Van der Vreken, Philip Vlummens, Elke De Bruyne, Kim De Veirman, Yanmeng Wang, Rong Fan, et al.
- Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis(2022)
Auteurs: Inge Oudaert, Hatice Satilmis, Philip Vlummens, Wouter De Brouwer, Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman, et al.
Pagina's: 45 - Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions(2022)
Auteurs: Jesús Bravo Melgar, Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman
- Kinome expression profiling to target new therapeutic avenues in multiple myeloma(2020)
Auteurs: Hugues de Boussac, Angélique Bruyer, Michel Jourdan, Anke Maes, Nicolas Robert, Claire Gourzones, Laure Vincent, Anja Seckinger, Guillaume Cartron, Dirk Hose, et al.
Pagina's: 784-795 - Exploring the therapeutic potential of targeting mitotic exit in combination with standard of care agents in high grade B cell malignancies.(2019)
Auteurs: Anke Maes, Karin Vanderkerken